Core Viewpoint - The announcement from Saifen Technology indicates that core technical personnel Yang Ke has officially retired due to reaching the legal retirement age, and he will no longer be recognized as a core technical staff member or hold any position within the company [1] Company Summary - Yang Ke's retirement marks a significant change in the company's technical leadership, as he was previously recognized as a core technical personnel [1] - The company will need to address the potential impact of this leadership change on its ongoing projects and technological development [1]

中信证券股份有限公司 关于苏州赛分科技股份有限公司 核心技术人员离职的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为苏州赛分 科技股份有限公司（以下简称"赛分科技"、"公司"）首次公开发行股票并在科 创板上市的保荐人，根据《首次公开发行股票注册管理办法》《上海证券交易所 科创板股票上市规则》等有关法律法规和规范性文件的要求，对公司核心技术人 员离职事项进行了专项核查，具体情况及核查意见如下： 一、杨克先生离职的具体情况 公司核心技术人员杨克先生因达到法定退休年龄，于近日正式退休，公司不 再认定其为核心技术人员，且杨克先生不再担任公司任何职务。 （一）核心技术人员的具体情况 （三）竞业限制及保密情况 根据公司与杨克先生签署的《竞业限制及保密协议》，双方对保密内容、竞 业限制等事项进行了明确的约定。截至本核查意见出具之日，公司未发现杨克先 生有违反《竞业限制及保密协议》的情形。 二、核心技术人员离职对公司的影响 公司高度重视研发工作，不断完善研发体系建设，研发运营团队结构完整， 研发平台各部门各司其职，公司的技术研发与生产运营工作均正常开展，不存在 对特定核心技术人员单一依赖的情形。目前， ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-036 重要内容提示： 一、杨克先生离职的具体情况 公司核心技术人员杨克先生因达到法定退休年龄，于近日正式退休，公司不 再认定其为核心技术人员，且杨克先生不再担任公司任何职务。公司及董事会对 杨克先生任职期间为公司发展所做出的努力和贡献表示衷心感谢。 1、核心技术人员的具体情况 杨克，赛分科技研究院士，美国布兰迪斯大学（Brandeis）博士，麻省理工 学院（MIT）博士后。1995 年至 2008 年，先后供职于美国 Memorial Sloan-Kettering Cancer Center，Pharmacoepeia, Inc.，Message Pharmaceutical, Inc. 和 Astrazeneca 苏州赛分科技股份有限公司 关于核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"赛分科技"或"公司"）核心 技术人员杨克先生因达到法定退休年龄，于近日正式退休离职，公司不 再认定其为核心 ...

Group 1 - Core technical personnel Yang Ke has officially retired due to reaching the legal retirement age and will no longer hold any position in the company [1] - As of the report, the market capitalization of the company is 7.7 billion yuan [1] Group 2 - For the fiscal year 2024, the revenue composition of the company is as follows: drug analysis accounts for 40.2%, antibody drugs for 20.85%, insulin/peptide/GLP-1 for 18.18%, recombinant proteins for 13.73%, and others for 6.6% [1]

Group 1 - The core viewpoint of the news is that Sai Fen Technology experienced a decline in stock price and negative net financing on September 22, 2023, indicating potential liquidity issues [1] - On September 22, 2023, Sai Fen Technology's stock price fell by 1.75%, with a trading volume of 34.52 million yuan. The net financing amount was -5.14 million yuan, with a total financing and margin balance of 41.92 million yuan [1] - The financing buy-in amount for Sai Fen Technology on the same day was 3.58 million yuan, while the financing repayment was 8.72 million yuan, leading to a current financing balance that constitutes 5.48% of the circulating market value [1] Group 2 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2] - For the period from January to June 2025, Sai Fen Technology achieved operating revenue of 183 million yuan, representing a year-on-year growth of 19.76%, and a net profit attributable to shareholders of 53.66 million yuan, up 40.91% year-on-year [2] - The company's revenue composition includes 33.10% from industrial purification, 32.65% from industrial purification fillers, and 16.73% from analytical chromatography, among other segments [2] Group 3 - As of June 30, 2025, Sai Fen Technology had 10,500 shareholders, a decrease of 4.63% from the previous period, with an average of 3,779 circulating shares per person, an increase of 4.86% [2] - The company has distributed a total of 27.90 million yuan in dividends since its A-share listing [3] - The largest circulating shareholder as of June 30, 2025, is the Southern Science and Technology Innovation Board 3-Year Open Mixed Fund, holding 791,100 shares, a decrease of 893,600 shares from the previous period [3]

Company Overview - Suzhou Saifen Technology Co., Ltd. is located in the Suzhou Industrial Park, Jiangsu Free Trade Zone, and was established on March 16, 2009. The company is set to be listed on January 10, 2025. Its main business involves the research and production of liquid chromatography materials used for drug analysis and purification [2]. Financial Performance - For the period from January to June 2025, the company achieved operating revenue of 183 million yuan, representing a year-on-year growth of 19.76%. The net profit attributable to the parent company was 53.66 million yuan, reflecting a year-on-year increase of 40.91% [2]. Business Segmentation - The revenue composition of Saifen Technology is as follows: Industrial purification segment accounts for 33.10%, industrial purification fillers 32.65%, analytical chromatography segment 16.73%, analytical chromatography columns 13.31%, analytical chromatography fillers 3.13%, and other segments contribute minor percentages [2]. Shareholder Information - As of June 30, 2025, the number of shareholders of Saifen Technology was 10,500, a decrease of 4.63% from the previous period. The average circulating shares per person increased by 4.86% to 3,779 shares [2]. Dividend Distribution - The company has cumulatively distributed dividends amounting to 27.90 million yuan since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder is the Southern Science and Technology Innovation Board 3-Year Open Mixed Fund (506000), holding 791,100 shares, which is a decrease of 893,600 shares compared to the previous period. The Galaxy Medical Mixed A Fund (011335) has exited the top ten circulating shareholders list [3]. Market Activity - On September 17, 2023, Saifen Technology's stock rose by 0.33%, with a trading volume of 45.03 million yuan. The financing buy-in amount for that day was 3.22 million yuan, while the financing repayment was 3.51 million yuan, resulting in a net financing buy-in of -0.29 million yuan. The total financing and securities lending balance as of September 17, 2023, was 43.54 million yuan [1].

Core Points - The company announced a cash dividend of CNY 0.026 per share for the first half of 2025, totaling CNY 10,828,066.18 for all shareholders [2][4]. Distribution Plan - The dividend distribution plan was authorized by the shareholders' meeting on May 20, 2025, and approved by the board on August 16, 2025 [2][3]. - The distribution is based on a total share capital of 416,464,084 shares [4]. Implementation Details - Shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date will receive the dividend [3][5]. - The cash dividend will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited [5]. Taxation Information - For individual shareholders holding unrestricted shares for over one year, the dividend is exempt from personal income tax, resulting in a net cash dividend of CNY 0.026 per share [8]. - For shares held for less than one year, the tax will be calculated upon transfer, with a potential tax rate of 20% for shares held for one month or less [9]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, leading to a net cash dividend of CNY 0.0234 per share [10].

Group 1 - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.026 yuan per share (including tax) [2] - The record date for the dividend is set for September 23, 2025, with the ex-dividend date and payment date both on September 24, 2025 [2]

证券代码：688758 证券简称：赛分科技 公告编号：2025-035 苏州赛分科技股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/23 | 2025/9/24 | 2025/9/24 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经苏州赛分科技股份有限公司（以下简称"公司"）2025 年 5 月 20 日召开的2024年年度股东大会授权公司董事会制定实施，并经公司 2025 年 8 月 16 日召开的第二届董事会 2025 年第四次会议审议通过。 二、 分配方案 1. 发放年度：2025年半年度 三、 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/23 | 2025/9/24 | 2025/9/24 | 四、 分配实施办法 2. 分派对象： 截至股权登记日 ...

中信证券股份有限公司 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； 关于苏州赛分科技股份有限公司 2025 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为苏州赛 分科技股份有限公司（以下简称"赛分科技"或"公司"或"上市公司"）首次 公开发行股票并在科创板上市的保荐人。根据《证券发行上市保荐业务管理办 法》、《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 8 月 13 日至 8 月 14 日期间对公司进行了现场检查。 （3）查阅公司与 ...